Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants

Andi L. Shane, Michael D. Cabana, Stéphane Vidry, Dan Merenstein, Ruben Hummelen, Collin L. Ellis, James T. Heimbach, Susanne Hempel, Susan V. Lynch, Mary Ellen Sanders, Daniel J Tancredi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The heterogeneity of human clinical trials to assess the efectiveness of probiotics presents challenges regarding interpretation and comparison. Evidence obtained from clinical trials among a population with a disease or specific risk factors may not be generalizable to healthy individuals. The evaluation of interventions in healthy persons requires careful selection of outcomes due to the absence of health indicators and the low incidence of preventable conditions. Given the tremendous resources invested in such trials, development of consistent approaches to assessing the efectiveness of probiotics would be benefcial. Furthermore, the reporting, presentation and communication of results may also afect the validity of the scientifc evidence obtained from a trial. This review outlines the challenges associated with the design, implementation, data analysis and interpretation of clinical trials in humans involving probiotics. Best practices related to their design are ofered along with recommendations for enhanced collaboration to advance research in this emerging feld.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalGut Microbes
Volume1
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Probiotics
Clinical Trials
Practice Guidelines
Communication
Incidence
Health
Research
Population
Clinical Studies

Keywords

  • Clinical trials
  • Guidelines
  • Human
  • Probiotics
  • Study design

ASJC Scopus subject areas

  • Gastroenterology
  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology

Cite this

Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. / Shane, Andi L.; Cabana, Michael D.; Vidry, Stéphane; Merenstein, Dan; Hummelen, Ruben; Ellis, Collin L.; Heimbach, James T.; Hempel, Susanne; Lynch, Susan V.; Sanders, Mary Ellen; Tancredi, Daniel J.

In: Gut Microbes, Vol. 1, No. 4, 2010, p. 243-253.

Research output: Contribution to journalArticle

Shane, AL, Cabana, MD, Vidry, S, Merenstein, D, Hummelen, R, Ellis, CL, Heimbach, JT, Hempel, S, Lynch, SV, Sanders, ME & Tancredi, DJ 2010, 'Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants', Gut Microbes, vol. 1, no. 4, pp. 243-253. https://doi.org/10.4161/gmic.1.4.12707
Shane, Andi L. ; Cabana, Michael D. ; Vidry, Stéphane ; Merenstein, Dan ; Hummelen, Ruben ; Ellis, Collin L. ; Heimbach, James T. ; Hempel, Susanne ; Lynch, Susan V. ; Sanders, Mary Ellen ; Tancredi, Daniel J. / Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. In: Gut Microbes. 2010 ; Vol. 1, No. 4. pp. 243-253.
@article{d28f045a59ff4b0598b9f45c1882ce2e,
title = "Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants",
abstract = "The heterogeneity of human clinical trials to assess the efectiveness of probiotics presents challenges regarding interpretation and comparison. Evidence obtained from clinical trials among a population with a disease or specific risk factors may not be generalizable to healthy individuals. The evaluation of interventions in healthy persons requires careful selection of outcomes due to the absence of health indicators and the low incidence of preventable conditions. Given the tremendous resources invested in such trials, development of consistent approaches to assessing the efectiveness of probiotics would be benefcial. Furthermore, the reporting, presentation and communication of results may also afect the validity of the scientifc evidence obtained from a trial. This review outlines the challenges associated with the design, implementation, data analysis and interpretation of clinical trials in humans involving probiotics. Best practices related to their design are ofered along with recommendations for enhanced collaboration to advance research in this emerging feld.",
keywords = "Clinical trials, Guidelines, Human, Probiotics, Study design",
author = "Shane, {Andi L.} and Cabana, {Michael D.} and St{\'e}phane Vidry and Dan Merenstein and Ruben Hummelen and Ellis, {Collin L.} and Heimbach, {James T.} and Susanne Hempel and Lynch, {Susan V.} and Sanders, {Mary Ellen} and Tancredi, {Daniel J}",
year = "2010",
doi = "10.4161/gmic.1.4.12707",
language = "English (US)",
volume = "1",
pages = "243--253",
journal = "Gut Microbes",
issn = "1949-0976",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants

AU - Shane, Andi L.

AU - Cabana, Michael D.

AU - Vidry, Stéphane

AU - Merenstein, Dan

AU - Hummelen, Ruben

AU - Ellis, Collin L.

AU - Heimbach, James T.

AU - Hempel, Susanne

AU - Lynch, Susan V.

AU - Sanders, Mary Ellen

AU - Tancredi, Daniel J

PY - 2010

Y1 - 2010

N2 - The heterogeneity of human clinical trials to assess the efectiveness of probiotics presents challenges regarding interpretation and comparison. Evidence obtained from clinical trials among a population with a disease or specific risk factors may not be generalizable to healthy individuals. The evaluation of interventions in healthy persons requires careful selection of outcomes due to the absence of health indicators and the low incidence of preventable conditions. Given the tremendous resources invested in such trials, development of consistent approaches to assessing the efectiveness of probiotics would be benefcial. Furthermore, the reporting, presentation and communication of results may also afect the validity of the scientifc evidence obtained from a trial. This review outlines the challenges associated with the design, implementation, data analysis and interpretation of clinical trials in humans involving probiotics. Best practices related to their design are ofered along with recommendations for enhanced collaboration to advance research in this emerging feld.

AB - The heterogeneity of human clinical trials to assess the efectiveness of probiotics presents challenges regarding interpretation and comparison. Evidence obtained from clinical trials among a population with a disease or specific risk factors may not be generalizable to healthy individuals. The evaluation of interventions in healthy persons requires careful selection of outcomes due to the absence of health indicators and the low incidence of preventable conditions. Given the tremendous resources invested in such trials, development of consistent approaches to assessing the efectiveness of probiotics would be benefcial. Furthermore, the reporting, presentation and communication of results may also afect the validity of the scientifc evidence obtained from a trial. This review outlines the challenges associated with the design, implementation, data analysis and interpretation of clinical trials in humans involving probiotics. Best practices related to their design are ofered along with recommendations for enhanced collaboration to advance research in this emerging feld.

KW - Clinical trials

KW - Guidelines

KW - Human

KW - Probiotics

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=79251480110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251480110&partnerID=8YFLogxK

U2 - 10.4161/gmic.1.4.12707

DO - 10.4161/gmic.1.4.12707

M3 - Article

AN - SCOPUS:79251480110

VL - 1

SP - 243

EP - 253

JO - Gut Microbes

JF - Gut Microbes

SN - 1949-0976

IS - 4

ER -